Denali Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNLI and other ETFs, options, and stocks.

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. 

CEO
Ryan J. Watts
CEORyan J. Watts
Employees
503
Employees503
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2013
Founded2013
Employees
503
Employees503

DNLI Key Statistics

Market cap
3.36B
Market cap3.36B
Price-Earnings ratio
-6.63
Price-Earnings ratio-6.63
Dividend yield
Dividend yield
Average volume
1.44M
Average volume1.44M
High today
$21.48
High today$21.48
Low today
$19.96
Low today$19.96
Open price
$20.32
Open price$20.32
Volume
1.21M
Volume1.21M
52 Week high
$23.77
52 Week high$23.77
52 Week low
$10.57
52 Week low$10.57

Stock Snapshot

Denali Therapeutics(DNLI) stock is priced at $21.22, giving the company a market capitalization of 3.36B. It carries a P/E multiple of -6.63.

As of 2026-03-09, Denali Therapeutics(DNLI) stock has fluctuated between $19.96 and $21.48. The current price stands at $21.22, placing the stock +6.3% above today's low and -1.2% off the high.

Denali Therapeutics(DNLI) shares are trading with a volume of 1.21M, against a daily average of 1.44M.

In the last year, Denali Therapeutics(DNLI) shares hit a 52-week high of $23.77 and a 52-week low of $10.57.

In the last year, Denali Therapeutics(DNLI) shares hit a 52-week high of $23.77 and a 52-week low of $10.57.

DNLI News

Simply Wall St 3d
Denali Therapeutics Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed?

Denali Therapeutics Inc. recently reported fourth-quarter and full-year 2025 results, with net losses of US$128.55 million for the quarter and US$512.54 million...

Denali Therapeutics Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed?

Analyst ratings

94%

of 18 ratings
Buy
94.4%
Hold
5.6%
Sell
0%

People also own

Based on the portfolios of people who own DNLI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.